Pentixapharm Holding AG (ETR:PTP) | WebDisclosure

Basculer en Français

10646	Companies
226459	Keywords
154934	Articles
119869	Press releases

Headlines Articles Press releases Pentixapharm Holding AG

Home
Companies
Pentixapharm Holding AG

PRESS RELEASE

published on 10/06/2025 at 11:00, 8 months 20 days ago

Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New Clinical Findings at EANM 2025
Pentixapharm presents new clinical findings on expanding CXCR4 radiopharmaceutical platform at EANM 2025, demonstrating potential in diagnosis and therapeutics in Primary Aldosteronism and bladder cancer

Pentixapharm CXCR4 Radiopharmaceutical EANM 2025 Clinical Findings
BRIEF

published on 09/26/2025 at 08:05, 9 months ago

Pentixapharm Advances PentixaTher in AML Trial

Clinical Trial Radiopharmaceuticals Acute Myeloid Leukemia PentixaTher CXCR4-targeting
BRIEF

published on 09/26/2025 at 08:05, 9 months ago

Pentixapharm fait progresser PentixaTher dans l'essai sur la LAM

Essai Clinique Produits Radiopharmaceutiques Ciblage CXCR4 Leucémie Myéloïde Aiguë PentixaTher
PRESS RELEASE

published on 09/26/2025 at 08:00, 9 months ago

Pentixapharm Announces Advancement of PentixaTher to Fourth Dose Level in Acute Myeloid Leukemia Trial
Pentixapharm advances PentixaTher to fourth dose level in AML trial, reinforcing safety profile and potential clinical efficacy for CXCR4-targeted radiotherapeutic in high unmet need indication

Pentixapharm CXCR4 Acute Myeloid Leukemia Radiotherapeutic PentixaTher
BRIEF

published on 05/27/2025 at 09:48, 1 year ago

Pentixapharm Unveils New Clinical Development Strategy

Oncology Pentixapharm CXCR4 Trials Theranostic Strategy Hematologic Malignancies
BRIEF

published on 05/27/2025 at 09:48, 1 year ago

Pentixapharm dévoile une nouvelle stratégie de développement clinique

Oncologie Pentixapharm Essais CXCR4 Stratégie Théranostique Hémopathies Malignes
PRESS RELEASE

published on 05/27/2025 at 09:43, 1 year ago

EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm outlines new clinical development strategy
Pentixapharm outlines new clinical development strategy focusing on CXCR4 therapeutic and diagnostic oncology programs, discontinuing PTF301 trial in MZL, preparing new trials in hematologic malignancies and Bladder Cancer

Pentixapharm CXCR4 Oncology Programs Clinical Development Strategy Theranostic Precision
BRIEF

published on 04/25/2025 at 15:44, 1 year 2 months ago

Pentixapharm to Showcase Innovative Antibody GT-008 at AACR 2025

Cancer Therapy Pentixapharm GT-008 Antibody Glycan-Dependent CD24 Targeting
BRIEF

published on 04/25/2025 at 15:44, 1 year 2 months ago

Pentixapharm présentera son anticorps innovant GT-008 à l'AACR 2025

Thérapie Contre Le Cancer Pentixapharm Anticorps GT-008 Glycane-dépendant Ciblage CD24
PRESS RELEASE

published on 04/25/2025 at 15:39, 1 year 2 months ago

Pentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025
Pentixapharm to present novel CD24 antibody GT-008 for solid tumors at AACR 2025, showcasing glycan-dependent mechanism for targeted therapy

Solid Tumors Pentixapharm AACR 2025 GT-008 CD24 Antibody

Accesswire

Published on 06/26/2026 at 15:05, 24 minutes ago

Vox Royalty Sells I-80 Gold Offtake Stream
Published on 06/26/2026 at 14:05, 1 hour 24 minutes ago

SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 1 hour 29 minutes ago

Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 2 hours 29 minutes ago

Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 2 hours 44 minutes ago

Northern Dynasty Reports Oral Arguments Held

View all ACCESSWIRE

EQS Group

Published on 06/26/2026 at 15:18, 10 minutes ago

Form 8.3 - The Vanguard Group, Inc.: IP Group plc
Published on 06/26/2026 at 15:17, 11 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc
Published on 06/26/2026 at 15:17, 11 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Personal Finance plc
Published on 06/26/2026 at 15:16, 12 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Gamma Communications plc
Published on 06/26/2026 at 15:15, 13 minutes ago

Form 8.3 - The Vanguard Group, Inc.: easyJet plc

Les Echos

Published on 06/26/2026 at 14:44, 44 minutes ago

Safran information
Published on 06/26/2026 at 14:44, 44 minutes ago

Information Safran
Published on 06/26/2026 at 12:16, 3 hours 12 minutes ago

Rapport semestriel SIEHM au 30 avril 2026
Published on 06/26/2026 at 07:00, 8 hours 29 minutes ago

Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 8 hours 29 minutes ago

Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel

View all LES ECHOS COMFI WIRE